BioSpace News Archive

While medical devices have seen incredible advancements over the last 100 years, ocular drug delivery systems have seen minimal progress; the standard eye dropper used has gone largely unchanged in the last century.

Ubitus K.K. (hereinafter Ubitus), a world-leading metaverse solution provider, supports Smart Surgery Technology to roll out its VR driven surgery simulation application – Sim Surgery.

American CryoStem Corporation (OTC Pink: CRYO), a clinical-stage therapeutics company with a proprietary end-to-end core biotechnology platform of tissue-based cellular technologies powering its clinical pipeline, announced today that Agustin Legido, MD, PhD, MBA has joined its Scientific and Medical Advisory Board.

The Lung Cancer Research Foundation (LCRF) and ALK Positive Inc. (ALK Positive) announce funding of two ALK-positive related lung cancer projects.

The global healthcare automation market size was exhibited at USD 41.71 billion in 2022 and it is expected to hold around USD 91.6 billion by 2030, expanding growth at a CAGR of 10.33% from 2022 to 2030.

According to the principles for the appointment of the Nomination Committee in Oncopeptides AB, the Nomination Committee for the annual general meeting 2023 shall be composed of members appointed by the three largest shareholders in terms of voting rights as of September 30 who are willing to participate in the Nomination Committee, along with the Chairman of the Board of Directors.

The global immune checkpoint inhibitors market size accounted for USD 37.31 billion in 2022 and is expected to attain around USD 148.1 billion by 2030 with a noteworthy CAGR of 18.81% from 2022 to 2030.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Sunlenca® (lenacapavir), in combination with other antiretroviral(s) (ARV), has been granted approval by the U.S. Food and Drug Administration (FDA) for the treatment of HIV-1 infection in heavily treatment-experienced (HTE) adults with multi-drug resistant (MDR) HIV-1 infection.

InSitu Biologics, Inc. is pleased to announce that it has entered into an agreement with the Mayo Foundation for Medical Education and Research to further develop its prolonged-release drug delivery technology for anti-cancer therapeutics.

Ryvu Therapeutics [WSE:RVU], a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced the completion of its public offering of 4,764,674 Series J common shares (“Public Offering”).